Answers are grounded in this paper and cite their sources.
Hemostatic abnormalities after chimeric antigen receptor (CAR) T-cell therapy range from transient laboratory changes to clinically significant bleeding, venous or arterial thrombosis, disseminated intravascular coagulation (DIC), and thrombotic microangiopathy (TMA). Their interpretation is complicated by overlapping cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hematotoxicity (ICAHT), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), infection, organ dysfunction, and antithrombotic exposure. Clinical and translational evidence indicates that endothelial activation, inflammatory coagulation signaling, altered fibrinolysis, and impaired hematopoietic or hepatic function contribute to heterogeneous hemostatic abnormalities after CAR T-cell therapy. Cytokine-driven endothelial activation and tissue-factor signaling may promote thrombin generation and platelet–leukocyte interactions, while thrombocytopenia, impaired marrow recovery, and fibrinogen depletion reduce hemostatic reserve. In a 100-patient cohort, 51% developed at least one abnormal coagulation parameter; in a separate 127-patient cohort, bleeding and thrombosis occurred in 9.4% and 6.3%, respectively, within three months. Prospective and registry studies have associated bleeding or inflammatory toxicity with baseline hematopoietic reserve, thrombocytopenia, anticoagulant exposure, and changes in platelet and fibrinogen levels. Clinical management requires balancing thrombotic urgency against bleeding risk and hemostatic reserve, with targeted treatment of inflammatory toxicity, individualized anticoagulation, and hemostatic support when indicated. Persistent or recurrent hyperinflammation warrants assessment for IEC-HS, while microangiopathic hemolysis and renal injury should prompt evaluation for TMA rather than automatic attribution to DIC. Prothrombotic inflammatory and endothelial signaling may coexist with reduced hemostatic reserve after CAR T-cell therapy, without following a uniform temporal sequence. Serial laboratory measurements can inform clinical assessment, but their ability to predict bleeding or thrombosis beyond conventional measures remains uncertain. The proposed phase-adapted framework provides a basis for individualized monitoring and management, although its clinical utility, treatment thresholds, and effects on major bleeding and thrombotic outcomes require prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: